Ubrogepant Taken Early in a Migraine Attack, Before the Headache Starts
Observes how ubrogepant works when taken in the early warning phase of migraine.
Key facts
- Who runs it
- AbbVie
- Where
- Aliso Viejo, Grand Island, and Naperville, United StatesSee the 3 sites
- Trial code
- Registry title
- Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- Status
- Recruiting
- People taking part
- 189 people, planned
- Started
- 27 Jan 2026
- Expected to end
- Mar 2027
- Type of study
- Observational
- Record updated
- 10 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who already take ubrogepant for acute migraine treatment and have used it for at least 3 months.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Migraine or chronic migraine, with 4 to 10 migraine days per month with moderate to severe headache pain in each of the 3 months before Visit 1.
- Earlier treatment
- Must be currently prescribed ubrogepant and have used it for at least 3 months to treat migraine attacks. People with chronic migraine may take preventive treatment.
Main reasons for not taking part
- Currently taking part in another clinical or non-interventional study
- Using a strong CYP3A4 inhibitor at the same time
- New persistent daily headache
- Trigeminal autonomic cephalgia, status migrainosus or painful cranial neuropathy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- History of 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1; --a. Participants with a diagnosis of chronic migraine who report having 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1 due to concomitant preventive treatment are allowed in the study
- Participant is currently prescribed ubrogepant and has been using ubrogepant for at least 3 months for the acute treatment of migraine in adults, according to the US Food and Drug Administration (FDA)-approved indication
- Adult participants with current clinical diagnosis of migraine or chronic migraine according to International Classification of Headache Disorders (ICHD)-3
Who cannot take part
- Currently participating in a concurrent clinical or non-interventional study
- Concomitant use with a strong Cytochrome P450 3A4 (CYP3A4 ) inhibitor
- Current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus or painful cranial neuropathy as defined by ICHD-3
Where in United States
- Neurology and Pain Specialty Center /ID# 278508Aliso Viejo, United StatesContact: Krystal SpentaTaking people
- Tri City Research Center, LLC /ID# 278800Grand Island, United StatesContact: Krystal SpentaTaking people
- Chicago Headache Center & Research Inst /ID# 272345Naperville, United StatesContact: Krystal SpentaTaking people
About the trial
What the trial wants to find out
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks.
Read full original descriptionShow less
Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US.
Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
The group in the trial
- Ubrogepant
Participants will receive Ubrogepant as prescribed by their physician according to local label.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PHASES: Prodrome in tHe reAl World: aSsESsing Ubrogepant Acute Use
- Plain-language title
- Ubrogepant Taken Early in a Migraine Attack, Before the Headache StartsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 February 2026